Kymera Therapeutics Claimed Company
Kymera Therapeutics is a clinical stage biopharmaceutical company pioneering a transformative new modality, “targeted protein degradation” (TPD), with the ability to pursue targets long considered undruggable and to treat disease in entirely new ways. Our team has developed a proprietary drug discovery engine, Pegasus, to enable the design of highly selective, small molecule protein degraders with potent activity against a broad range of disease indications. We are committed to selecting targets with the broadest possible impact across multiple disease indications with high unmet medical need to realize the full potential of TPD. Kymera is led by an expert team of dedicated scientists and drug hunters, with decades of experience in the foundational areas of targeted protein degradation and drug development. read more
HR or Marketing? Claim Your Free Employer Account
Kymera Therapeutics CEO & Leadership Team Ratings
Nello Mainolfi, PhD and the Kymera Therapeutics leadership team are scored a C+ by 11 employees placing it in the Top 50% of companies sized 51-200 Employees on Comparably. The Leadership score includes details about how employees evaluate their executive team, CEO and manager.
Based on 42 ratings, the Leadership score of 74/100 combines employee feedback on their CEO (65/100), Manager (78/100), and Executive Team (67/100).
Nello Mainolfi, PhD Kymera Therapeutics CEO Rating
Bottom 35% Compared to other companies of similar size in BostonC-
65 / 100
Nello Mainolfi, PhD the CEO of Kymera Therapeutics received an average score of 65 from Kymera Therapeutics employees.Kymera Therapeutics Manager Rating
Top 35% Compared to other companies of similar size in BostonB
78 / 100
Kymera Therapeutics Executive Team Rating
Bottom 40% Compared to other companies of similar size in BostonC
67 / 100
×